Trade DMAC anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
DiaMedica Therapeutics Inc. (DMAC) is trading at US$6.47, down 4.15% today as of Aug 28, 12:53 EDT. The company has a market capitalisation of US$351.6M. Over the past 52 weeks, DMAC has traded between US$5.14 and US$10.42. On Syfe you can trade DMAC with $0 commission and add it to your watchlist.
| Previous close | US$6.75 |
|---|---|
| Market cap | US$351.6M |
| 52-week range | US$5.14 – US$10.42 |
| Volume | 113.81K |
| Exchange | US |
Add to Watchlist
Set Price Alert
DiaMedica Therapeutics Inc.
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Year: 2007
DiaMedica Therapeutics Doses First Patients in Phase 2 Fetal Growth Restriction Trial
Jun 23, 1:26 PM · MT Newswires
DiaMedica Therapeutics Receives US FDA Guidance on DM199 Nonclinical Requirements
Jun 16, 1:05 PM · MT Newswires
DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment
May 20, 1:05 PM · MT Newswires
DiaMedica Says Health Canada Grants Regulatory Clearance to Begin Phase 2 Trial of DM199 for Preeclampsia
Mar 5, 1:13 PM · MT Newswires
DiaMedica Therapeutics Inc. (DMAC) stock is trading at US$6.47, -4.15% from the previous close of US$6.75.
The market cap for DiaMedica Therapeutics Inc. (DMAC) stock is approximately US$351.6M.
The 52-week high for DiaMedica Therapeutics Inc. (DMAC) stock is US$10.42.
The 52-week low for DiaMedica Therapeutics Inc. (DMAC) stock is US$5.14.
DiaMedica Therapeutics Inc. (DMAC) does not currently pay a dividend.
Stay on top of DMAC
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
